Nephrology & Dialysis Devices Market Size, Share, Growth and Forecast, 2025-2035

Kidney failure burden keeps dialysis machines in demand

The global nephrology and dialysis devices market was valued at USD 22.95 billion in 2025 and is projected to increase from USD 24.16 billion in 2026 to USD 38.25 billion by 2035, registering a CAGR of 5.24% during 2026–2035. Demand comes from a growing number of people with chronic kidney disease and kidney failure, longer survival on dialysis and steady replacement of machines, dialyzers and water systems in treatment centers. North America held the largest regional share, 38.0% in 2025, because the United States treats a large dialysis population with high equipment and service spending. Asia Pacific is the fastest-growing region at 6.39% a year, as China and India add dialysis centers and expand public coverage for kidney failure. The technology picture changed in May 2025, when Fresenius Medical Care received U.S. clearance for an updated hemodiafiltration machine. As a result, U.S. providers are now evaluating convective therapy that was already common in Europe and Japan.

Which kidney care products does this analysis cover?

The analysis counts hemodialysis machines and dialyzers, peritoneal dialysis cyclers and sets, continuous renal replacement therapy systems, renal function monitors, dialysis water treatment systems, vascular access products and related equipment. Values are based on manufacturer selling prices, including disposables sold for use with each platform.

Dialysis services, clinic staffing, drugs and kidney transplants sit outside the scope of this analysis. The value chain runs from membrane and component makers through device manufacturers and distributors to hospitals, dialysis center chains, specialty clinics and home therapy programs that train patients and deliver supplies.

Hemodialysis leads while home peritoneal care gains

Why do hemodialysis devices lead product spending?

Based on product, the market is categorized into hemodialysis devices, peritoneal dialysis devices, continuous renal replacement therapy (CRRT) systems, renal function monitoring devices, dialysis water treatment systems, vascular access devices and others. Hemodialysis Devices led with a 52.0% share of 2025 value, because most kidney failure patients receive in-center treatment three times a week with single-use dialyzers. Peritoneal Dialysis Devices grow fastest at 6.08% a year, as payers and providers push home therapy. Intensive care units also need continuous renal replacement therapy for acute kidney injury.

Where are dialysis machines used most often?

Based on end user, the market is categorized into hospitals and dialysis centers, home healthcare settings and specialty nephrology clinics. Hospitals & Dialysis Centers led with a 74.0% share of 2025 value, because large center chains run machine fleets and buy disposables under long contracts. Home Healthcare Settings grow fastest at 6.44% a year, as more patients choose peritoneal dialysis or home hemodialysis after training. Specialty clinics add demand for monitoring and vascular access care.

Chronic kidney disease and aging lift treatment volumes

How does chronic kidney disease prevalence sustain demand?

Chronic kidney disease prevalence sustains demand, because a share of patients progresses to kidney failure and needs dialysis for life. The Centers for Disease Control and Prevention estimates that 14% of U.S. adults, or about 37 million people, have the condition and about 87% of them do not know it. This late detection means many patients start dialysis urgently, often in hospital emergency or inpatient units. As a result, treatment volumes keep rising even where prevention programs improve.

Why do diabetes and high blood pressure lift kidney failure cases?

Diabetes and high blood pressure lift kidney failure cases, because both conditions damage kidney filters over many years. The same CDC estimates show that about 38% of adults with diabetes and 21% of adults with high blood pressure have chronic kidney disease. Rising diabetes rates in Asia, the Middle East and Latin America therefore add future dialysis patients in those regions. In turn, governments plan new treatment capacity, and suppliers sell more machines, dialyzers and water systems.

Download Free Sample

How does global policy attention support treatment access?

Global policy attention supports treatment access, because kidney care had long been absent from major health agendas. The International Society of Nephrology reported that the 78th World Health Assembly adopted the first resolution on kidney health in May 2025. The resolution encourages member states to improve prevention, early detection and access to kidney replacement therapy. As a result, ministries in lower-income countries have stronger grounds to fund dialysis centers and equipment purchases through 2035.

Why does aging raise the need for kidney replacement therapy?

Aging raises the need for kidney replacement therapy, because kidney function declines with age and older adults carry more chronic disease. The CDC estimates that 34% of U.S. adults aged 65 and older have chronic kidney disease, compared with 6% of adults aged 18 to 44. Many older patients also live with heart disease, which makes them likely candidates for chronic kidney disease monitoring and later dialysis. In turn, aging populations in Japan, Europe and North America keep treatment demand high.

Hemodiafiltration and home therapy reshape purchasing

How is hemodiafiltration shifting U.S. machine purchasing?

Hemodiafiltration is shifting U.S. machine purchasing, because providers want therapy that removes larger toxins than standard hemodialysis. In June 2025, Fresenius Medical Care announced a broader U.S. rollout of its 5008X CAREsystem after an updated FDA clearance in May 2025. The company cited the CONVINCE study, in which high-volume hemodiafiltration patients showed a 23% lower mortality rate than high-flux hemodialysis patients. As a result, U.S. center chains now weigh convective capability in fleet replacement plans.

Why are home dialysis programs rising in importance?

Home dialysis programs are rising in importance, because payers and patients both favor treatment outside crowded centers. In November 2024, Quanta Dialysis Technologies announced FDA clearance for home use of its compact hemodialysis system. Quanta noted that only 2.4% of about 550,000 U.S. dialysis patients received home hemodialysis, based on 2022 national renal data. This low base leaves wide room for growth in home treatment. In turn, suppliers are designing smaller machines with simpler training and remote monitoring.

Download Free Sample

Can new dialyzer membranes open demand without new machines?

Dialyzer makers have a clear opening in new membrane designs, because providers can adopt them without replacing installed machines. In July 2026, Nipro received FDA 510(k) clearance for the ELISIO-HX dialyzer, a medium cutoff product that removes larger middle molecules while retaining albumin. In July 2026, the company announced U.S. commercialization and said providers can use existing machines and workflows for the new therapy. As a result, membrane innovation can lift value per treatment even when machine fleets stay unchanged.

Where can monitoring and access products add value?

Monitoring and access products give suppliers room to add value, because many dialysis complications start with vascular access failure or late detection. Clinics need fistula surveillance, catheters and vascular grafts that stay open longer between interventions. Regular kidney function testing also helps nephrologists plan treatment well before kidney failure arrives. In turn, suppliers that link access, monitoring and therapy data can strengthen ties with large providers.

Staffing, water quality and payment limits slow uptake

Why do staffing shortages limit treatment capacity?

Staffing shortages limit treatment capacity, because each dialysis shift needs trained nurses and technicians at the chair. Many centers in North America and Europe struggle to hire enough staff, which caps the number of shifts they can run. Home therapy programs also need training nurses who teach patients and support them remotely. As a result, providers delay new center openings and favor equipment that cuts setup time and simplifies daily operation.

How do water quality requirements raise setup costs?

Water quality requirements raise setup costs, because hemodialysis uses large volumes of purified water for each treatment. Centers must install reverse osmosis systems, distribution loops and regular testing to meet safety standards. These costs are hardest to carry in rural areas and lower-income countries where water supply is unreliable. In turn, many new centers there start small, which slows machine purchases and favors suppliers that bundle water systems.

Why do payment limits slow upgrades in many countries?

Payment limits slow upgrades in many countries, because governments pay dialysis providers fixed rates per treatment. Providers with tight margins often extend machine lives and choose lower-priced dialyzers in public tenders. Several countries in Asia and Latin America still cover dialysis only partly, so patients pay part of the cost. As a result, value growth in these markets trails the growth in treated patients.

How does late diagnosis keep patients in costly urgent care?

Late diagnosis keeps patients in costly urgent care, because many people learn about kidney failure only when symptoms become severe. Patients who start dialysis urgently usually begin in hospitals with temporary catheters rather than planned fistulas. This path raises infection risk and reduces the chance of choosing home therapy later. In turn, screening with renal biomarkers and primary care testing matters for the long-term mix of therapies.

North America leads as Asia Pacific adds capacity

Why does North America hold the largest regional share?

North America held a 38.0% share of 2025 value and grows at 4.79% a year through 2035. The United States drives this position, because a large dialysis population receives treatment in center chains with high equipment and service spending. Fresenius Medical Care began deploying its 5008X machine to a first wave of U.S. clinics in 2025, which opens a new replacement cycle. Home hemodialysis remains a small share of U.S. treatment, so new home systems add room for growth.

Why do China and India drive Asia Pacific kidney care growth?

Asia Pacific held a 24.0% share of 2025 value and is the fastest-growing region at 6.39% a year. China and India add dialysis centers as public insurance programs expand coverage for kidney failure. Japan has a large treated kidney failure population and a strong domestic supply base led by Nikkiso, Nipro and Asahi Kasei Corporation. This mix of volume growth and local manufacturing keeps competition intense across the region.

Download Free Sample

What shapes demand across Europe?

Europe held a 28.0% share of 2025 value and grows at 4.59% a year, the slowest pace of the five regions. Germany, France, Italy and Spain account for much of the spending, and hemodiafiltration is already common in many European centers. National health systems buy through tenders that reward price and service. However, long machine lives and fixed treatment payments keep value growth below the global average.

Where is Latin America adding demand?

Latin America held a 6.0% share of 2025 value and grows at 5.69% a year through 2035. Brazil and Mexico lead regional spending, because diabetes rates are high and private center networks are expanding. Coverage gaps still limit access in poorer areas, which keeps many patients on late, urgent treatment.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 5.89% a year through 2035. Gulf states fund modern centers with high diabetes-related demand, while much of Africa has limited dialysis capacity. The 2025 kidney health resolution gives health ministries a framework to plan new treatment services.

Download Free Sample

FDA clearances and ownership changes since 2024

Membranes, connected machines and home systems advance

• High-volume hemodiafiltration adds convective clearance to standard hemodialysis, which removes larger toxins and has been linked with lower mortality in clinical study.
• Medium cutoff membranes remove larger middle molecules while keeping albumin in the blood, which lets providers improve therapy on existing machines.
• Compact home hemodialysis systems use smaller machines with simpler setup, which makes treatment at home practical for more patients and caregivers.
• Connected chairside data exchange sends treatment data from machines to clinic records, which cuts manual charting and helps nurses track each session.
• Automated peritoneal dialysis cyclers run exchanges overnight with remote monitoring, which lets clinicians adjust therapy without frequent clinic visits.

Dialysis suppliers compete on therapy breadth and service

Competition is led by a small number of companies with broad kidney care portfolios, large installed bases and long service relationships. Fresenius Medical Care AG & Co. KGaA combines machines, dialyzers and water systems with its own clinic network. In February 2025, Baxter International Inc. completed the sale of its kidney care business, which launched as Vantive after the Carlyle acquisition. B.Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd and Asahi Kasei Corporation compete strongly in machines, dialyzers and blood lines, with deep roots in Europe and Japan. Becton, Dickinson and Company and Boston Scientific Corporation serve vascular access and related procedures. Cantel Medical Corporation is linked with water treatment and reprocessing products, while Dornier MedTech GmbH serves kidney stone care. As a result, buyers favor suppliers that cover several therapies and provide reliable field service.

Companies profiled and their roles in this market

Home care and convective therapy set the growth pace

Credence Research's view is that home therapy and convective treatment will set the pace of growth through 2035, because providers want better outcomes without adding center staff. The overall market grows at 5.24% a year, supported by rising chronic kidney disease prevalence, aging and new policy attention after the 2025 kidney health resolution. Peritoneal dialysis and home settings grow faster than in-center hemodialysis. Companies that combine machines, membranes, water systems and remote support will win the most provider contracts.

How Credence Research sized kidney care equipment

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by product, end user and region. Regional and segment splits are Credence Research estimates informed by U.S. public health statistics, World Health Assembly decisions, U.S. regulator clearances and company press releases. No primary interviews or surveys were used in preparing this edition of the report.

Kidney replacement equipment outlook to 2035

By 2035, the nephrology and dialysis devices market is projected to reach USD 38.25 billion, with growth led by hemodiafiltration machines, new dialyzer membranes and home therapy systems. Hemodialysis devices will remain the largest product area, as center chains renew machine fleets and buy disposables for each treatment. North America keeps the highest spending per patient, while Asia Pacific adds the most new treatment capacity. Home settings will take a larger share of value, because payers and patients prefer treatment outside centers. As a result, advantage will depend on outcomes, simplicity and service.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.